Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Pilot Biotechnology

Request full access

An industrial biotechnology company engaged in the development, production, and sales of health care products

Suzhou Shi, ChinaFounded 2015Biotech & Life Sciences

About Suzhou Pilot Biotechnology

Suzhou Pilot Biotechnology Co., Ltd. (Leadermetbio), established in June 2015, operates at the forefront of the synthetic biology sector, focusing on replacing traditional chemical manufacturing with green, bio-based production methods. The company was founded by Dr. Xie Xinkai, a notable figure in the biotechnology field. Dr. Xie earned his Ph.D. from the University of California, Los Angeles, and was a postdoctoral fellow under Professor Jay Keasling, a foundational figure in synthetic biology. His background includes being the primary inventor of the biosynthesis of the cholesterol-lowering drug simvastatin and a recipient of the U.S. Presidential Green Chemistry Challenge Award in 2012.

The firm's core business involves the research, development, production, and sale of products for the pharmaceutical, nutritional supplement, and animal health markets. It utilizes an AI-driven synthetic biology platform that integrates gene editing, enzyme engineering, metabolic engineering, and fermentation optimization to develop efficient microbial strains and production processes. This model allows the company to provide bio-manufactured products to other businesses, serving as a key supplier in their respective value chains. Revenue is generated through the sale of these bio-synthesized products.

Pilot Biotechnology's product portfolio is extensive, including items such as the veterinary antibiotic intermediate D-ethyl ester, the feed additive active vitamin D3, and the anti-aging ingredient NMN. The company has successfully industrialized over 20 biosynthetic processes and operates multiple production bases, including a significant facility in Hunan that began production in 2023 and has a total capacity exceeding 10,000 tons. This allows the company to export products to more than 20 countries. To support its global reach, the company maintains a research and development headquarters in Suzhou, an R&D center in the United States, and production facilities in Hunan and Anhui.

Significant milestones include the establishment of its Hunan production base in October 2017, the opening of its U.S. R&D center in August 2019, and the acquisition of Anhui Libo Pharmaceutical Co., Ltd. in June 2023 to expand its raw material production capabilities. The company has also secured substantial funding through multiple rounds, including a Series D round in August 2023 and a subsequent D+ round of over 100 million yuan to accelerate commercialization and global market expansion.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.7/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Health Diagnostics, Synthetic Biology, Hard Tech, biomanufacturing, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES D✓Equity / VC Aug 2023 $28M $110M Lilly Asia Ventures · Sherpa Venture Partners ↗
SERIES CEquity / VC Feb 2022 $14M $55M Lilly Asia Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Pilot Biotechnology website traffic

Latest recorded traffic for Suzhou Pilot Biotechnology is 150 monthly website visits, down 91.7% over the last three months.

Latest monthly visits150 3-month web change-91.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Pilot Biotechnology in the Suzhou Shi ecosystem

Live from Dealroom

The Suzhou Pilot Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Lilly Asia Ventures
  • Sherpa Venture Partners

Other known investors1 additional known investor

  • Asia Green Fund
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Pilot Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Pilot Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.